The data on osimertinib are good in daily clinical practice (also confirmed by the high grade of clinical benefit on ESMO scale[3]), but a reduction in pharmacological costs is mandatory if we want to consider osimertinib more cost-effective in first-line treatment for EGFR-mutated advanced NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.